Author

B. Feldt-Rasmussen

3 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Early magnesium changes may contribute to SGLT2 inhibitor–induced left ventricular mass regression in CKD

Disturbances in the bone and mineral homeostasis are central drivers of cardiovascular disease in chronic kidney disease (CKD), contributing to vascular calcification and left ventricular hypertrophy. In DECODE-CKD, the sodium-glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin induced significant left ventr...

K. Bartholdy, N. Johansen, D. Modin et al. · European Heart Journal · 0 citations

Open access Oct 2026

Incremental risk stratification using the H2FPEF score in patients with chronic kidney disease and unexplained dyspnea

In patients with non-dialysis dependent CKD and unexplained dyspnea, a higher H2FPEF score was independently associated with an increased risk of all-cause mortality and incident HF.

A. Al-Rubai, J. Christensen, F. Davidovski et al. · European Heart Journal · 0 citations

Open access Oct 2026

Diastolic dysfunction and structural response to SGLT2 inhibition in chronic kidney disease: the DECODE-CKD trial

It is suggested that SGLT2 inhibitors may preferentially attenuate ventricular remodeling in patients with early HFpEF-related structural changes.

K. Bartholdy, N. Johansen, D. Modin et al. · European Heart Journal · 0 citations